Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma

On the heels of Merck & Co. rival Keytruda’s green light as an adjuvant treatment for earlier-stage melanoma, Bristol Myers Squibb’s Opdivo has ginned up data suggesting it won’t be locked in advanced disease for long.